Phase 1 Open-label Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an Immunomodulator and Tissue Repair Inducer, in Healthy Volunteers
Phase 1 open-label dose-escalation study to evaluate the safety and pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an immunomodulator and tissue repair inducer, in healthy volunteers.
100 Clinical Results associated with Immunalgia Therapeutics S.A.
0 Patents (Medical) associated with Immunalgia Therapeutics S.A.
100 Deals associated with Immunalgia Therapeutics S.A.
100 Translational Medicine associated with Immunalgia Therapeutics S.A.